STOCKS TELEGRAPH

Tag: BCTX

  • 3 Stocks Investors Should Know About: BriaCell Therapeutics (BCTX), Cardiol Therapeutics (CRDL), Oragenics Inc (OGEN)

    3 Stocks Investors Should Know About: BriaCell Therapeutics (BCTX), Cardiol Therapeutics (CRDL), Oragenics Inc (OGEN)

    Healthcare innovation remains a key driver of long-term growth within the life sciences industry, supported by ongoing demand for improved treatment options across chronic and complex diseases. Companies developing differentiated therapies often attract increased attention as they progress through successive phases of clinical validation.

    BriaCell Therapeutics Corp (BCTX)

    BriaCell Therapeutics Corp (NASDAQ: BCTX) flaunted a slowness of -0.72% at $4.16, as the Stock market unbolted on May 11, 2026. During the day, the stock rose to $4.31 and sank to $4.13. Taking a long-term approach, BCTX posted a 52-week range of $3.60-$37.20.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 39.57%. Meanwhile, its Annual Earnings per share during the time was 39.57%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 93.92%. This publicly-traded company’s shares outstanding now amount to $7.25 million, simultaneously with a float of $7.15 million. The organization now has a market capitalization of $30.16 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is increasingly differentiating itself through a mechanism-focused strategy aimed at treating cardiovascular inflammation without broadly suppressing immune function. As inflammation becomes a more established therapeutic target in heart disease, companies with targeted approaches may gain strategic advantages within the evolving cardiovascular treatment landscape.

    Market Momentum

    As of May 11, 2026, CRDL closed at $1.3350, up 1.14%, with trading volume of 370,080 shares compared to an average volume of 686,413 shares. The company currently carries a market capitalization of $149.093M and a beta of 0.43, reflecting relatively controlled volatility for a clinical-stage biotech stock. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.38 highlights substantial upside potential tied to future clinical and regulatory developments.

    Mechanism of Action

    Cardiol’s lead therapies are designed to target inflammatory signaling pathways associated with cardiac injury and disease progression. By modulating inflammasome activity and reducing pro-inflammatory cytokines such as IL-1 and IL-6, the company aims to address underlying drivers of inflammation linked to recurrent pericarditis, myocarditis, and other cardiovascular disorders.

    Strategic Differentiation

    Unlike some traditional anti-inflammatory approaches that broadly suppress immune activity, Cardiol’s strategy is intended to selectively reduce harmful inflammation while preserving normal immune function. This differentiated profile may offer advantages in long-term safety and tolerability, particularly for chronic cardiovascular conditions requiring extended treatment duration.

    Outlook

    As scientific understanding of cardiovascular inflammation continues to evolve, Cardiol’s mechanism-driven platform could strengthen its positioning within the biotech sector. Continued clinical validation may further support investor confidence and future partnership opportunities.

    Oragenics Inc (OGEN)

    Witnessing the stock’s movement on the chart, on May 11, 2026, Oragenics Inc (NYSEAMERICAN: OGEN) had a quiet start as it plunged -6.60% to $0.56. During the day, the stock rose to $0.60 and sank to $0.56. Taking a long-term approach, OGEN posted a 52-week range of $0.50-$9.60.

    The Healthcare sector firm’s twelve-monthly sales growth has been 64.78% for the last half of the decade. Meanwhile, its Annual Earnings per share during the time was 64.78%.  This publicly-traded company’s shares outstanding now amount to $4.38 million, simultaneously with a float of $4.32 million. The organization now has a market capitalization of $2.52 million.

  • BriaCell Therapeutics Corp. (BCTX) Stock Undergoes Volatility Ahead of Expanded Cancer Platform Technology Announcement

    BriaCell Therapeutics Corp. (BCTX) Stock Undergoes Volatility Ahead of Expanded Cancer Platform Technology Announcement

    BriaCell Therapeutics Corp. (BCTX) stock prices were up by a hefty 8.96% as of the market closing on June 16th, 2021, bringing the price per share up to USD$6.57 at the end of the trading day. After-hours trading, however, saw the stock drop by 9.28%, bringing it down to USD$5.96.

    Oncology Therapeutics

    The company announced on June 16th, 2021 the advancement of its targeted oncology therapeutics into various respective immunotherapy cell lines. Among these are Bria-Pros for prostrate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. The treatment was most effective in breast cancer when patient HLA-type matched with the targeted immunotherapy, owing to the potential afforded to Briacell to identify patients most likely to respond to the treatment.

    HLA-Type Testing

    This innovative approach makes use of human leukocyte antigen (HLA-type) testing, which is both simple to use and widely available, making it a highly accessible resource. With the use of its proprietary cell engineering technology, the company is now developing off-the-shelf personalized immunotherapy for various cancer indications, which utilizes the HLA-matching platform technology.

    Bria-Pros

    Bria-Pros is an off-the-shelf personalized treatment for prostate cancer, which is the second most common cancer among men in the US and one of the leading causes of cancer deaths in men. Existing treatments for metastatic prostate cancer include immunotherapy, hormone therapy, chemotherapy, and targeted treatments. However, there is much ground left to be broken in prostate cancer therapies, seeing how none of the existing ones are curative.

    Bria-Mel

    Bria-Mel is personalized immunotherapy for melanoma, with off-the-shelf availability. With more than 80,000 melanoma diagnoses being administered in the US alone, the disease claims the lives of more than 8000 patients every year. Immunotherapy, targeted therapy, and chemotherapy are options in the treatment for advanced melanoma, with there being a large unaddressed need for new safe and effective therapies for melanoma.

    Bria-Lung

    Bria-Lung is designed as personalized immunotherapy for lung cancer, being available off-the-shelf. Being the third most common type of cancer in the world, more than 130,000 Americans succumb to it every year. The most common form of lung cancer is called non-small cell lung cancer (NSCLC) and its spread (metastasis). With treatments including targeted therapies, immunotherapy, and chemotherapy, no treatment is likely to cure the cancers, indicating a large unmet need.

    Future Outlook for BCTX

    Armed with the development of accessible treatments that the company hopes will address large sections of unmet need, BCTX is poised to push for the proliferation of the treatments to expand and consolidate their market footprint. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • BriaCell Therapeutics Corp. (BCTX) stock increased over 10% in Pre-Market: Let’s find out why

    BriaCell Therapeutics Corp. (BCTX) stock increased over 10% in Pre-Market: Let’s find out why

    Share of BriaCell Therapeutics Corp. (BCTX) surpassed 10% in the pre-market trading session today. BCTX stock saw a push of 13.82% to reach $5.93 a share at the time of this writing. It seems that BCTX stock continued the rising momentum as it went up by 18.95% at the previous closing. But what made the stock high in the stock market? Let’s try to find it.

    What’s happening?

    There is no particular news by the  BriaCell stock today to justify the bull. No signs of analyst upgrades or upswing BCTX per share targeted price to explain the rally. However, BrialCell announced on March 30 about its selection to present the analysis result of its research related to breast cancer at the American Association for Cancer Research (AACR) Annual Meeting 2021. The dates announced for the meeting were April 10 to 15 and May 17 – 21.

    The first week of the meeting is ongoing and there is a strong possibility that investors are responding to the results announced by the company in the meeting. The analysis result to be announced in the meeting would be related to the clinical analysis and pathological data of BriaCell’s lead product, Bria-IMT for treatment of advanced breast cancer as well as Phase I/IIa clinical study of Bria-IMTin combination with immune checkpoint inhibitors which include pembrolizumab, a Merck’s product, and INCMGA00012, a product of Incyte Corporation.

    BCTX stock previous news:

    On February 26, 2021, BCTX stock closed the underwritten public offering of its common units. 4,852,353 common units were offered in that offering with US$4.25 per unit purchase price. Each unit consisted of one share of common stock of BCTX along with one warrant to the purchase of one share of BCTX’s common stock. 1,030,000 pre-funded units were offered at the public price of  US$4.24 each and consisted of a pre-funded purchase warrant of common stock and one Warrant. The US$25 million gross proceeds resulted from this offering without deducting the underwriting discounts and other related expenses.

    Conclusion:

    BCTX stock price is continuously rising despite no recent news by BriaCell Therapeutics. It would be interesting to see how long this trend would continue in the future. The final results of research related to breast cancer would greatly influence the future of the BriaCell stock.